ELASTRIN THERAPEUTICS, INC.

GREENVILLE, SC · Founded 2017 · Biotech · Private

Targeted nanoparticles conjugated to elastin antibodies for localized delivery of chelating agents to calcified arterial tissue

Claim this profile

Follows are private to you and power your alerts

Updated · elastrin.com

Sector
Biotech
Headquarters
GREENVILLE, SC
Founded
2017
Latest Form D
$50K, Sep 2024
Total capital
$10.9M
Federal grants
$284K
1 award · 2019
Rank in peer group#118 of 392
Private capital raised
$10.6M
5 Form D · last Sep 2024
25 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $10.9M$284K1st Form D$500K2nd Form D$3.6M
201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $10.9M$284K

Latest events

  • Private capital raisedForm D · SEC · 5th filing$50K
  • Private capital raisedForm D · SEC · 4th filing$4.8M
  • Private capital raisedForm D · SEC · 3rd filing$1.7M
  • Private capital raisedForm D · SEC · 2nd filing$3.6M
  • Private capital raisedForm D · SEC · 1st filing$500K
  • Federal grantHealth and Human S · Phase I · Targeted Chelation for Reversal of Vascular Calcification$284K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

19months

from ELASTRIN THERAPEUTICS, INC.’s first federal award to its first private round.

First federal award · Jul 2019
Health and Human S · $284K
First Form D · Mar 2021
$500K · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grants#118 · top 30%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Naren VyavahareResearcherExecutive Officer, DirectorLinked by $284K in grants as PI
  • Klaus-Dieter LangnerDirectorNamed in SEC Form D filings
  • Matthias BreugelmansExecutive Officer, DirectorNamed in SEC Form D filings
  • Patrick BurgermeisterDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • ACURASTEM INCSimilar federal contract value in Biotech · null in contracts
  • OPHIDION, INC.Similar federal contract value in Biotech · null in contracts
  • WESTERN ONCOLYTICS, LTDSimilar federal contract value in Biotech · null in contracts
  • Paulex Bio Inc.Similar federal contract value in Biotech · null in contracts
  • CYTOTERRA INC.Similar federal contract value in Biotech · null in contracts
  • Verismo Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .